Changchun University of Chinese Medicine, 1035 Bo Shuo Road, Changchun City, Jilin Province, China.
Endocrinology, First Affiliated Hospital to Changchun University of Chinese Medicine, 1478 Gongnong Road, Changchun City, Jilin Province, China.
Medicine (Baltimore). 2022 May 13;101(19):e29152. doi: 10.1097/MD.0000000000029152.
Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies have shown that traditional Chinese patent medicines have been effective in treating DN, with few side effects. There is no systematic review on the treatment of DN with Chinese patent medicines. The current systematic review aims to evaluate the efficacy and safety of Chinese patent medicines for the treatment of DN.
We will develop a search strategy to search major Chinese and English databases from inception to February 25, 2022 for randomized controlled trials examining the use of traditional Chinese patent medicine for the treatment of DN. The search will be conducted in accordance with the participants, interventions, comparisons, outcomes (PICOS) framework. Two researchers will use EndnoteX9 software to extract data and independently evaluate the quality of the included trials. Finally, the Bayesian network meta-analysis will be carried out by using software such as ReviewManager, Stata16.0, and WinBUGS1.4.3.
The primary outcomes will be urine albumin excretion rate, urea nitrogen, serum creatinine, total effective rate, and adverse events, and the secondary outcomes will be body mass index, fasting blood glucose, and 2-hPG during 75-g OGTT. These outcomes will be examined to provide a reliable basis for the treatment of DN with different traditional Chinese patent medicines.
This review will compare the efficacy and safety of different traditional Chinese patent medicines for treating DN. The results of the study will provide a basis for the selection of adjuvant treatment options for DN.
糖尿病肾病（DN）是糖尿病最严重的并发症之一。它已成为人类的一个全球性公共卫生问题。DN 是终末期肾病的主要原因。目前，尚无特效药物或现代药物疗法。近年来，研究表明，中药在治疗 DN 方面具有一定疗效，且副作用较少。目前尚未对中药治疗 DN 进行系统评价。本系统评价旨在评估中药治疗 DN 的疗效和安全性。
我们将制定一个检索策略，从建库到 2022 年 2 月 25 日，检索主要的中英文数据库，以查找评估传统中药治疗 DN 的随机对照试验。检索将按照参与者、干预措施、比较、结局（PICOS）框架进行。两名研究人员将使用 EndnoteX9 软件提取数据，并独立评估纳入试验的质量。最后，将使用 ReviewManager、Stata16.0 和 WinBUGS1.4.3 等软件进行贝叶斯网络荟萃分析。
主要结局指标将是尿白蛋白排泄率、尿素氮、血清肌酐、总有效率和不良反应，次要结局指标将是体重指数、空腹血糖和 75-g OGTT 时的 2-hPG。这些结局指标将被检查，为不同中药治疗 DN 提供可靠依据。
本综述将比较不同中药治疗 DN 的疗效和安全性。该研究的结果将为 DN 的辅助治疗方案选择提供依据。
